Ian D. Pedley

Newcastle Upon Tyne, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Healthcare provision for cancer survivors with chronic bowel symptoms post pelvic radiotherapy. "… and then you're kind of cast adrift": A qualitative study.

Healthcare provision for cancer survivors with chronic bowel symptoms post pelvic radiotherapy. "… and then you're kind of cast adrift": A qualitative study.

Journal: European journal of oncology nursing : the official journal of European Oncology Nursing Society

Published: December 28, 2024

A Systematic Review of Population-Based Studies of Chronic Bowel Symptoms in Cancer Survivors following Pelvic Radiotherapy.

A Systematic Review of Population-Based Studies of Chronic Bowel Symptoms in Cancer Survivors following Pelvic Radiotherapy.

Journal: Cancers

Published: July 11, 2023

Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol.

Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol.

Journal: The Lancet. Oncology

Published: January 23, 2023

Using the AR-V7 biomarker to determine treatment in metastatic castrate resistant prostate cancer, a feasibility randomised control trial, conclusions from the VARIANT trial.

Using the AR-V7 biomarker to determine treatment in metastatic castrate resistant prostate cancer, a feasibility randomised control trial, conclusions from the VARIANT trial.

Journal: NIHR open research

Published: January 03, 2023

Observation versus screening spinal MRI and pre-emptive treatment for spinal cord compression in patients with castration-resistant prostate cancer and spinal metastases in the UK (PROMPTS): an open-label, randomised, controlled, phase 3 trial.

Observation versus screening spinal MRI and pre-emptive treatment for spinal cord compression in patients with castration-resistant prostate cancer and spinal metastases in the UK (PROMPTS): an open-label, randomised, controlled, phase 3 trial.

Journal: The Lancet. Oncology

Published: December 21, 2021

Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.

Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.

Journal: Lancet (London, England)

Published: October 12, 2021

Prostate Ultrahypofractionation - Rising to Challenges Presents Opportunities in the COVID-19 Era.

Prostate Ultrahypofractionation - Rising to Challenges Presents Opportunities in the COVID-19 Era.

Journal: Clinical oncology (Royal College of Radiologists (Great Britain))

Published: September 03, 2020

Optimising Radium 223 Therapy for Metastatic Castration-Resistant Prostate Cancer -5-year Real-World Outcome: Focusing on Treatment Sequence and Quality of Life.

Optimising Radium 223 Therapy for Metastatic Castration-Resistant Prostate Cancer -5-year Real-World Outcome: Focusing on Treatment Sequence and Quality of Life.

Journal: Clinical oncology (Royal College of Radiologists (Great Britain))

Published: April 15, 2020

Prostate cancer androgen receptor splice variant 7 biomarker study - a multicentre randomised feasibility trial of biomarker-guided personalised treatment in patients with advanced prostate cancer (the VARIANT trial) study protocol.

Prostate cancer androgen receptor splice variant 7 biomarker study - a multicentre randomised feasibility trial of biomarker-guided personalised treatment in patients with advanced prostate cancer (the VARIANT trial) study protocol.

Journal: BMJ open

Published: December 21, 2019

Magnetic Resonance-only Workflow: Implementation in a UK Centre.

Magnetic Resonance-only Workflow: Implementation in a UK Centre.

Journal: Clinical oncology (Royal College of Radiologists (Great Britain))

Published: October 16, 2019

ACORN: Observational Study of Bevacizumab in Combination With First-Line Chemotherapy for Treatment of Metastatic Colorectal Cancer in the UK.

ACORN: Observational Study of Bevacizumab in Combination With First-Line Chemotherapy for Treatment of Metastatic Colorectal Cancer in the UK.

Journal: Clinical colorectal cancer

Published: November 14, 2018

Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.

Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.

Journal: Lancet (London, England)

Published: September 18, 2018

Showing 1-12 of 16

Last Updated: 09/26/2026